Global Central Nervous System Treatment Market to Grow at a CAGR of 8.1% During the Period 2024-2032, Driven by Increasing Number of Cases Related to Disorders of the Central Nervous System

The global central nervous system treatment market is expected to be driven by increasing incidence of neurological disorders, development of new treatment systems, regulations seeking to support treatment systems for central nervous system disorders, and technological innovations. North America, Europe and Asia are projected to be key markets.

Leading companies are engaged in developing advanced solutions for the treatment of disorders related to the central nervous system. For example, in 2022, Otsuka Pharmaceutical Co., Ltd. and Ai-BrainScience Inc. announced an exclusive sales collaboration agreement in Japan for a cognitive function testing application that used eye movement (development code: AiBS-01). The product was said to have the potential to become the first dementia diagnosis application to get regulatory approval in Japan. The eye tracking technology developed by Ai-BrainScience used the AiBS-01 cognitive function testing application installed on an iPad or other tablet.

In 2022, Otsuka Pharmaceutical Co., Ltd., its subsidiary Otsuka America Pharmaceutical, Inc. and Lundbeck, Inc., a U.S. subsidiary of H. Lundbeck A/S in Denmark, announced that the U.S. Food and Drug Administration (FDA) had approved the supplemental new drug application (sNDA) of REXULTI® (brexpiprazole) to treat schizophrenia in paediatric patients falling in the 13 to 17 age group.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

In 2020, Teva Pharmaceutical Industries launched AJOVY®, used for the preventive treatment of migraine in adults. The association with Teva marked the first commercial market entry of Ypsomed’s larger 2.25 ml autoinjector YpsoMate 2.25. Such developments are expected to drive the global central nervous system treatment market. In 2022, Teva Pharmaceuticals and MedinCell announced that the U.S. Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia.

In 2018, Bain Capital, LP and Pfizer Inc. announced the creation of Cerevel Therapeutics, LLC (“Cerevel”), a new biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system. Pfizer sought to contribute a portfolio of pre-commercial neuroscience assets to Cerevel, which included three clinical-stage compounds and several pre-clinical compounds devised to target a wide range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction.

Innovative therapies are expected to boost the global central nervous system treatment market. For example, in 2022, Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. announced that the companies had entered into a definitive agreement under which Pfizer would acquire Biohaven, the maker of NURTEC® ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults.

In 2021, Angelini Pharma announced the acquisition of Arvelle Therapeutics, the Swiss-based biopharmaceutical company focused on bringing innovative treatments to patients suffering from central nervous system disorders. After the acquisition, Angelini Pharma would have the exclusive license to commercialize cenobamate in the European Union, in Switzerland and in the United Kingdom.

Key Findings of the Report:

• The global central nervous system treatment market is expected to be driven by increasing incidence of neurological disorders and development of new treatment systems.

• Innovative solutions are expected to boost market growth. 

• North America, Europe and Asia are likely to be key markets.

Market Segmentation:

• By type, the market is segmented into Neurovascular Diseases (further broken down by type into Hemorrhagic Stroke, Ischemic Stroke and Others), Neurodegenerative Diseases (further broken down by type into Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis and Others), Mental Health (further broken down by type into Epilepsy, Mood Disorders, Anxiety Disorders and Others), Infectious Diseases (further broken down by type into Meningitis, Encephalitis and Others) and Others.

• By drug class, the market is divided into Immunomodulatory Drugs, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Antidepressants, Analgesics and Others.

• By drug type, the market is classified into Biologics and Non-Biologics.

• By region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.